Efficacy and Safety of Dapagliflozin According to Background Use of Cardiovascular Medications in Patients With Type 2 Diabetes-Reference-Cited by-同舟云学术

Efficacy and Safety of Dapagliflozin According to Background Use of Cardiovascular Medications in Patients With Type 2 Diabetes

Published:2022-09-01 Issue:9 Volume:7 Page:914
ISSN:2380-6583
Container-title:JAMA Cardiology
language:en
Short-container-title:JAMA Cardiol

Author:

Oyama Kazuma¹²,Raz Itamar³⁴,Cahn Avivit³⁴,Goodrich Erica L.¹,Bhatt Deepak L.⁵,Leiter Lawrence A.⁶,McGuire Darren K.⁷,Wilding John P. H.⁸,Gause-Nilsson Ingrid A. M.⁹,Mosenzon Ofri³⁴,Sabatine Marc S.¹,Wiviott Stephen D.¹

Affiliation:

1. TIMI Study Group, Division of Cardiovascular Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts

2. Department of Cardiovascular Medicine, Tohoku University Graduate School of Medicine, Sendai, Japan

3. Diabetes Unit, Department of Endocrinology and Metabolism, Hadassah Medical Center, Jerusalem, Israel

4. Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel

5. Division of Cardiovascular Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts

6. Li Ka Shing Knowledge Institute, St Michael’s Hospital, University of Toronto, Toronto, Ontario, Canada

7. Division of Cardiology, University of Texas Southwestern Medical Center, Parkland Health and Hospital System, Dallas

8. Department of Cardiovascular and Metabolic Medicine, University of Liverpool, Liverpool, United Kingdom

9. BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden

Publisher

American Medical Association (AMA)

Subject

Cardiology and Cardiovascular Medicine

Link

https://jamanetwork.com/journals/jamacardiology/articlepdf/2794142/jamacardiology_oyama_2022_oi_220035_1663082222.4116.pdf

Reference20 articles.

1. Canagliflozin and cardiovascular and renal events in type 2 diabetes.;Neal;N Engl J Med,2017

2. Dapagliflozin and cardiovascular outcomes in type 2 diabetes.;Wiviott;N Engl J Med,2019

3. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes.;Zinman;N Engl J Med,2015

4. Cardiovascular outcomes with ertugliflozin in type 2 diabetes.;Cannon;N Engl J Med,2020

5. Association of SGLT2 inhibitors with cardiovascular and kidney outcomes in patients with type 2 diabetes: a meta-analysis.;McGuire;JAMA Cardiol,2021

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Influence of sodium/glucose cotransporter-2 inhibitors on the incidence of acute kidney injury: a meta-analysis;Frontiers in Pharmacology;2024-06-25

2. Comparison of baseline clinical characteristics among people with type 2 diabetes on second-line therapy previously added with dapagliflozin or another oral glucose-lowering drug: AGORA study;Clínica e Investigación en Arteriosclerosis;2024-06

3. Sodium-glucose co-transporter protein 2 (SGLT2) inhibitors for people with chronic kidney disease and diabetes;Cochrane Database of Systematic Reviews;2024-05-21

4. Exploration of Pharmacological Mechanisms of Dapagliflozin against Type 2 Diabetes Mellitus through PI3K-Akt Signaling Pathway based on Network Pharmacology Analysis and Deep Learning Technology;Current Computer-Aided Drug Design;2024-01-09

5. Combination therapy with kidney protective therapies: optimizing the benefits?;Current Opinion in Nephrology & Hypertension;2023-09-28